Bone-digesting osteoclasts harbour specialized lysosome-related organelles termed secretory lysosomes (SLs). SLs store cathepsin K and give rise to the osteoclast ruffled border (RB) upon fusion with the bone-oriented plasmalemma. Despite serving as a membrane precursor for RB genesis, and therefore fertile grounds for the discovery of new homeostatic regulators of bone mass, our understanding of the molecular composition of osteoclast SLs remains incomplete. Here, by integrating the organelle proteome of enriched SLs isolated from mouse osteoclasts with human GWAS of estimated bone mineral density, we identified member a2 of the solute carrier 37 family (Slc37a2) as a new SL sugar transporter associated with the physiological regulation of bone mass. In situ, we demonstrate that among bone-lineage cells, Slc37a2 expression is restricted to osteoclasts where it localizes to the limiting membrane of SLs and the RB. Using live-cell microscopy, we unexpectedly find that Slc37a2+ve SLs adopt a dynamic tubular organization in osteoclasts that radiates throughout the cytoplasm and fuses with the bone-apposed plasmalemma. Physiologically, bones from mice lacking Slc37a2 (Slc37a2KO) exhibit a profound increase in trabecular bone mass, which affords protection against age-associated bone loss. At the cellular level, this dramatic increase in bone mass is driven primarily by impaired bone resorption by osteoclasts coupled with imbalanced remodelling-based osteoblastic bone formation. Mechanistically, SLs in Slc37a2KO osteoclasts are engorged and dysfunctional owing to disturbances in the luminal export of monosaccharide sugars, a prerequisite necessary for SL organelle resolution, tubulation and delivery to the RB. Accordingly, Slc37a2KO osteoclasts exhibit disturbances in RB maturation and decreased delivery and secretion of cathepsin K. Altogether, our findings: (i) unmask Slc37a2 as a SL sugar transporter critical for physiological bone metabolism, (ii) highlight previously unappreciated plasticity of the osteoclast’s specialized lysosome-related organelle(s) and; (iii) posit Slc37a2 as potential therapeutic target for metabolic bone diseases.